Charcot-Marie-Tooth disease type 2D, a hereditary axonal neuropathy, is caused by mutations in glycyl-tRNA synthetase (GARS). The mutations are distributed throughout the protein in multiple functional domains. In biochemical and cell culture experiments, some mutant forms of GARS have been indistinguishable from wild-type protein, suggesting that these in vitro tests might not adequately assess the aberrant activity responsible for axonal degeneration. Recently, mouse and fly models have offered new insights into the disease mechanism. There are still gaps in our understanding of how mutations in a ubiquitously expressed component of the translation machinery result in axonal neuropathy. Here, we review recent reports, weigh the evidence for and against possible mechanisms and suggest areas of focus for future work.
Charcot-Marie-Tooth disease (CMT), one of the most common inherited neurological disorders, includes a genetically diverse group of peripheral neuropathies characterized by progressive weakness and atrophy in the hands and feet [1] . Pathophysiological studies categorize CMT as type I (demyelinating) or type 2 (axonal) [2] . There is overlap between axonal forms of CMT and a similar group of clinical syndromes classified as distal hereditary motor neuropathy or distal spinal muscular atrophy (dSMA), which are distinguished from CMT2 only by the absence of sensory loss [3] . CMT type 2D often causes more weakness in the distal upper extremities, a finding that is unusual among the CMTs, which usually present with length-dependent axonal degeneration affecting the feet more than the hands [3] .
In 2003, the glycyl-tRNA synthetase gene GARS was found to be mutated in CMT2D [4] . GARS is responsible for covalently linking glycine with corresponding tRNAs in an ATP-dependent reaction. Charged tRNA gly is then used in protein synthesis in the ribosome. GARS is thus ubiquitously expressed and absolutely necessary for protein translation in all cells. Since the CMT2D gene discovery, the challenge has been to determine how missense mutations in this critical and widely expressed protein cause selective degeneration of axons in peripheral nerves, a common conundrum with hereditary neurodegenerative diseases linked to ubiquitous proteins and presenting selective neuronal vulnerability. Here, we review work done to determine a mechanism for axonal degeneration in CMT2D and critically assess the likely mechanisms and suggest avenues for future investigation.
Genetics of CMT2D
GARS is one of 37 tRNA synthetase genes. It encodes both cytosolic and mitochondrial isoforms of the protein, which differ by a 54 amino acid N-terminal mitochondrial targeting sequence (Figure 1 ). In the protein region common to both isoforms, there are four functional domains: a WHEP-TRS domain that is highly conserved across tRNA synthetases (amino acids 13-63), two domains that form the catalytic core (amino acids 92-168 and 241-324) and an anticodon binding domain (amino acids 557-655). To date, 11 mutations in GARS have been reported (Table 1) . There are varying degrees of genetic evidence to indicate that the mutations are pathogenic. The mutations E71G, L129P and G240R, which segregate in pedigrees with LOD scores over 5, are the most tightly linked to the disease [4] [5] [6] [7] , although the L129P mutation is incompletely penetrant. Variants identified by sequencing GARS in small families and isolated patients with peripheral neuropathy, including A57 V, P244L, I280F, D500N, G526R, S581L, G598A and H418R (which also has reduced penetrance), are less clearly implicated [4, [8] [9] [10] [11] [12] .
Cell culture studies of GARS function and localization
In determining the functional consequences of GARS mutations, the initial focus was on the ability of the mutant enzyme to charge tRNA gly . tRNA charging can be assayed in two ways: (1) aminoacylation as measured by quantitative capture of tritiated glycine and (2) radioactively labeled inorganic phosphate release as a proxy for charging activity. These approaches were used to evaluate the activity of mutant GARS compared to wild-type enzyme. Of the seven mutations studied in aminoacylation assays with tritiated glycine, E71G, P234KY, D500N and S581L were all active, whereas L129P, G240R and G526R were inactive [13] . The inactivity of G526R was confirmed with the phosphate release assay [14] . These assays suggest that there is no direct correlation between disease pathogenesis and the in vitro charging capacity of the mutant proteins. Moving forward, it might be useful to determine whether these mutant enzymes can charge tRNAs in neurons and specifically in the axon.
Recent structural studies of GARS indicated that a majority of disease-causing mutations lie on the dimer 
